A Comprehensive Review on Nanostructured Lipid Carriers
Abstract
Nanostructured lipid carriers (NLCs) mark a pivotal evolution in lipid-based drug delivery, surpassing the constraints of solid lipid nanoparticles (SLNs) to optimize therapeutic performance. Formulated with a mix of solid and liquid lipids, NLCs disrupt the rigid crystalline structure of SLNs, facilitating enhanced drug encapsulation, greater stability, and tailored release kinetics for both hydrophobic and hydrophilic compounds. This review thoroughly examines NLCs, detailing their composition, scalable production methods, and assessment techniques. Employing biodegradable lipids and surfactants, NLCs enable environmentally sustainable manufacturing without organic solvents, ensuring biocompatibility and safety. Their adaptability supports a wide range of biomedical uses, such as targeted drug delivery, gene therapy, and vaccine development, enhancing patient adherence and clinical outcomes. The review also explores recent patents and innovative advancements, highlighting NLCs’ potential to transform pharmaceutical formulations. Despite obstacles like long-term stability and regulatory challenges, continuous progress in lipid nanotechnology establishes NLCs as a robust platform for next-generation drug carriers. This work illuminates the interplay of stability, functionality, and safety in NLC development, providing insights into their revolutionary impact on modern pharmaceutics and their capacity to meet unaddressed clinical demands.
Keywords: Nanostructured lipid carriers (NLCs), lipid-based drug delivery, targeted drug delivery, gene therapy and vaccine development
Keywords:
Nanostructured lipid carriers (NLCs), lipid-based drug delivery, targeted drug delivery, gene therapy, vaccine developmentDOI
https://doi.org/10.22270/jddt.v15i10.7390References
1. June IM, Davange RM, Salunkhe KS, Chaudhari SR, Deshmukh PD. Nanostructured lipid carrier: Novel drug delivery system. J Adv Drug Deliv. 2016; 3:7-16.
2. Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Frontiers in molecular biosciences. 2020; 7:587997. https://doi.org/10.3389/fmolb.2020.587997 PMid:33195435 PMCid:PMC7662460
3. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. International journal of pharmaceutics. 2004; 278(1):71-7. https://doi.org/10.1016/j.ijpharm.2004.02.032 PMid:15158950
4. Sakellari GI, Zafeiri I, Batchelor H, Spyropoulos F. Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active. Food Hydrocoll Health. 2021; 1:1. https://doi.org/10.1016/j.fhfh.2021.100024 PMid:35028634 PMCid:PMC8721956
5. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. International journal of nanomedicine. 2007; 2(4):595-607.
6. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Research in pharmaceutical sciences. 2018; 13(4):288-303. https://doi.org/10.4103/1735-5362.235156 PMid:30065762 PMCid:PMC6040163
7. Müller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles. Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers. 2016:161-85. https://doi.org/10.1007/978-3-662-47862-2_11
8. Olechowski F, Müller RH, Pyo SM. BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products. Beilstein Journal of Nanotechnology. 2019; 10(1):2152-62. https://doi.org/10.3762/bjnano.10.208 PMid:31807401 PMCid:PMC6880839
9. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. International journal of pharmaceutics.2007; 328(2):191-5. https://doi.org/10.1016/j.ijpharm.2006.08.007 PMid:16978810
10. Patel P, Patel M. Nanostructured lipid carriers-a versatile carrier for oral delivery of lipophilic drugs. Recent Patents on Nanotechnology. 2021; 15(2):154-64. https://doi.org/10.2174/1872210514666200909154959 PMid:32912129
11. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artificial cells, nanomedicine, and biotechnology. 2016; 44(1):27-40. https://doi.org/10.3109/21691401.2014.909822 PMid:24813223
12. Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid-based drug delivery systems. Pharmaceutical Chemistry Journal. 2019; 53:440-53. https://doi.org/10.1007/s11094-019-02017-9
13. Czajkowska-Kośnik A, Szekalska M, Winnicka K. Nanostructured lipid carriers: A potential use for skin drug delivery systems. Pharmacological Reports. 2019; 71(1):156-66. https://doi.org/10.1016/j.pharep.2018.10.008 PMid:30550996
14. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids in health and disease. 2012; 11:1-8. https://doi.org/10.1186/1476-511X-11-159 PMid:23167765 PMCid:PMC3561225
15. Iglič A, Rappolt M, Perez PL. Advances in biomembranes and lipid self-assembly. Academic Press; 2018.
16. Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: Production, characterization and stability. New York, NY, USA: Springer International Publishing; 2015. https://doi.org/10.1007/978-3-319-10711-0
17. Sharma A, Baldi A. Nanostructured lipid carriers: A review. J Dev Drugs. 2018; 7(1):191.
18. Purohit DK. Nano-lipid carriers for topical application: Current scenario. Asian Journal of Pharmaceutics (AJP). 2016; 10(1).
19. Nguyen HM, Hwang IC, Park JW, Park HJ. Enhanced payload and photo-protection for pesticides using nanostructured lipid carriers with corn oil as liquid lipid. Journal of Microencapsulation. 2012; 29(6):596-604. https://doi.org/10.3109/02652048.2012.668960 PMid:22424134
20. Singh P, Gupta RK, Jan R, Raina SK. Adherence for medication among self-reporting rural elderly with diabetes and hypertension. Journal of Medical Society. 2017; 31(2):86-9. https://doi.org/10.4103/jms.jms_48_16
21. Vyas A, Kumar Sonker A, Gidwani B. Carrier‐based drug delivery system for treatment of acne. The scientific world journal. 2014; 2014(1):276260. https://doi.org/10.1155/2014/276260 PMid:24688376 PMCid:PMC3934386
22. Subramaniam B, Siddik ZH, Nagoor NH. Optimization of nanostructured lipid carriers: Understanding the types, designs, and parameters in the process of formulations. Journal of nanoparticle research. 2020; 22:1-29. https://doi.org/10.1007/s11051-020-04848-0
23. Noor NM, Sheikh K, Somavarapu S, Taylor KM. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 117:372-84. https://doi.org/10.1016/j.ejpb.2017.04.012 PMid:28412472
24. Das RJ, Baishya K, Pathak K. Recent advancement of lipid drug conjugate as nanoparticulate drug delivery system. Int Res J Pharm. 2013; 4(1):73-8.
25. Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bulletin of Faculty of Pharmacy, Cairo University. 2015; 53(2):147-59. https://doi.org/10.1016/j.bfopcu.2015.10.001
26. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. European journal of pharmaceutics and biopharmaceutics. 2000; 50(1):161-77. https://doi.org/10.1016/S0939-6411(00)00087-4 PMid:10840199
27. Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert opinion on drug delivery. 2005; 2(1):75-87. https://doi.org/10.1517/17425247.2.1.75 PMid:16296736
28. Mukherjee PK, Harwansh RK, Bhattacharyya S. Bioavailability of herbal products: approach toward improved pharmacokinetics. In Evidence-based validation of herbal medicine. 2015 Jan 1 (pp. 217-245). Elsevier. https://doi.org/10.1016/B978-0-12-800874-4.00010-6
29. Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert opinion on drug delivery. 2009; 6(2):165-76. https://doi.org/10.1517/17425240802712590 PMid:19239388
30. Bunjes H, Steiniger F, Richter W. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir. 2007; 23(7):4005-11. https://doi.org/10.1021/la062904p PMid:17316032
31. Rosiaux Y, Jannin V, Hughes S, Marchaud D. Solid lipid excipients as matrix agents for sustained drug delivery. Excipient Applications in Formulation Design and Drug Delivery. 2015: 237-71. https://doi.org/10.1007/978-3-319-20206-8_9
32. Sharma P, Ganta S, Denny WA, Garg S. Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. International journal of pharmaceutics. 2009; 367(1-2):187-94. https://doi.org/10.1016/j.ijpharm.2008.09.032 PMid:18930127
33. Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids and Surfaces B: Biointerfaces. 2010; 75(2):538-42. https://doi.org/10.1016/j.colsurfb.2009.09.033 PMid:19879736
34. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. International journal of pharmaceutics. 2007; 345(1-2):163-71. https://doi.org/10.1016/j.ijpharm.2007.05.061 PMid:17644288
35. Doktorovova S, Souto EB, Silva AM. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): In vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines. Pharmaceutical development and technology. 2018; 23(1):96-105. https://doi.org/10.1080/10837450.2017.1384491 PMid:28949267
36. Müller RH, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. International journal of pharmaceutics. 2002; 242(1-2):121-8. https://doi.org/10.1016/S0378-5173(02)00180-1 PMid:12176234
37. Da Silva Santos V, Ribeiro AP, Santana MH. Solid lipid nanoparticles as carriers for lipophilic compounds for applications in foods. Food research international. 2019; 122:610-26. https://doi.org/10.1016/j.foodres.2019.01.032 PMid:31229120
38. Houacine C, Adams D, Singh KK. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. Journal of Molecular Liquids. 2020; 316:113734. https://doi.org/10.1016/j.molliq.2020.113734
39. Negi LM, Tariq M, Talegaonkar S. Nano-scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. Colloids and Surfaces B: Biointerfaces. 2013; 111:346-53. https://doi.org/10.1016/j.colsurfb.2013.06.001 Mid:23850745
40. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. International journal of pharmaceutics. 2008; 346(1-2):124-32. https://doi.org/10.1016/j.ijpharm.2007.05.060 PMid:17651933
41. Negi LM, Jaggi M, Talegaonkar S. A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology. Nanotechnology. 2012; 24(1):015104. https://doi.org/10.1088/0957-4484/24/1/015104 PMid:23221112
42. Mendes M, Basso J, Silva J, Cova T, Sousa J, Pais A, Vitorino C. Biomimeting ultra-small lipid nanoconstructs for glioblastoma treatment: A computationally guided experimental approach. International Journal of Pharmaceutics. 2020; 587:119661. https://doi.org/10.1016/j.ijpharm.2020.119661 PMid:32693289
43. Kasongo WA, Pardeike J, Müller RH, Walker RB. Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Journal of pharmaceutical sciences. 2011; 100(12):5185-96. https://doi.org/10.1002/jps.22711 PMid:22020815
44. Rosen MJ, Kunjappu JT. Surfactants and interfacial phenomena. John Wiley & Sons; 2012. https://doi.org/10.1002/9781118228920
45. Severino P, Pinho SC, Souto EB, Santana MH. Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids and Surfaces B: Biointerfaces. 2011; 86(1):125-30. https://doi.org/10.1016/j.colsurfb.2011.03.029 PMid:21543196
46. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. Aaps Pharmscitech. 2011; 12(1):62-76. https://doi.org/10.1208/s12249-010-9563-0 PMid:21174180 PMCid:PMC3066374
47. JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). European Journal of Pharmaceutics and Biopharmaceutics. 2008; 70(2):633-40. https://doi.org/10.1016/j.ejpb.2008.05.008 PMid:18577447
48. Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die pharmazie-an international journal of pharmaceutical sciences. 2006; 61(5):375-86.
49. del Pozo-Rodríguez A, Solinís MA, Gascón AR, Pedraz JL. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 71(2):181-9. https://doi.org/10.1016/j.ejpb.2008.09.015 PMid:18940256
50. Fang CL, A Al-Suwayeh S, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent patents on nanotechnology. 2013; 7(1):41-55. https://doi.org/10.2174/187221013804484827 PMid:22946628
51. Pinheiro M, Ribeiro R, Vieira A, Andrade F, Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug design, development and therapy. 2016: 2467-75. https://doi.org/10.2147/DDDT.S104395 PMid:27536067 PMCid:PMC4977088
52. Keservani RK, Sharma AK, Kesharwani RK, editors. Nanocarriers for brain targeting: principles and applications. CRC Press; 2019. https://doi.org/10.1201/9780429465079
53. Mendes IT, Ruela AL, Carvalho FC, Freitas JT, Bonfilio R, Pereira GR. Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids and Surfaces B: Biointerfaces. 2019; 177:274-81. https://doi.org/10.1016/j.colsurfb.2019.02.007 PMid:30763792
54. Joshi MD, Prabhu RH, Patravale VB. Fabrication of nanostructured lipid carriers (NLC)-based gels from microemulsion template for delivery through skin. In Pharmaceutical Nanotechnology: Basic Protocols 2019 (pp. 279-292). New York, NY: Springer New York. https://doi.org/10.1007/978-1-4939-9516-5_19 PMid:31148022
55. Shadambikar G, Marathe S, Ji N, Almutairi M, Bandari S, Zhang F, Chougule M, Repka M. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. International journal of pharmaceutics: 2021; 3:100074. https://doi.org/10.1016/j.ijpx.2021.100074 PMid:33748741 PMCid:PMC7973123
56. Li Q, Cai T, Huang Y, Xia X, Cole SP, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials. 2017; 7(6):122. https://doi.org/10.3390/nano7060122 PMid:28554993 PMCid:PMC5485769
57. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. Journal of controlled release. 2005; 108(1):112-20. https://doi.org/10.1016/j.jconrel.2005.07.023 PMid:16169111
58. Ren G, Sun Z, Wang Z, Zheng X, Xu Z, Sun D. Nanoemulsion formation by the phase inversion temperature method using polyoxypropylene surfactants. Journal of colloid and interface science. 2019; 540:177-84. https://doi.org/10.1016/j.jcis.2019.01.018 PMid:30640065
59. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharmaceutical research. 2002; 19(6):875-80. PMid:12134960
60. Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods. 2022; 199:3-8. https://doi.org/10.1016/j.ymeth.2021.05.003 PMid:33992771
61. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced pharmaceutical bulletin. 2015; 5(3):305. https://doi.org/10.15171/apb.2015.043 PMid:26504751 PMCid:PMC4616893
62. Garg J, Pathania K, Sah SP, Pawar SV. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Future Journal of Pharmaceutical Sciences. 2022; 8(1):25. https://doi.org/10.1186/s43094-022-00414-8
63. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Advanced pharmaceutical bulletin. 2020; 10(2):150. https://doi.org/10.34172/apb.2020.021 PMid:32373485 PMCid:PMC7191226
64. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. European journal of pharmaceutics and biopharmaceutics. 2003; 55(1):125-31. https://doi.org/10.1016/S0939-6411(02)00130-3 PMid:12551713
65. Van-An D, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020; 25(20):4781. https://doi.org/10.3390/molecules25204781 PMid:33081021 PMCid:PMC7587569
66. Wang L, Ma Y, Gu Y, Liu Y, Zhao J, Yan B, Wang Y. Cryoprotectant choice and analyses of freeze-drying drug suspension of nanoparticles with functional stabilisers. Journal of microencapsulation. 2018; 35(3):241-8. https://doi.org/10.1080/02652048.2018.1462416 PMid:29624090
67. Zhang L, Liu L, Qian Y, Chen Y. The effects of cryoprotectants on the freeze-drying of ibuprofen-loaded solid lipid microparticles (SLM). European journal of pharmaceutics and biopharmaceutics. 2008; 69(2):750-9. https://doi.org/10.1016/j.ejpb.2007.12.003 PMid:18280121
68. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews. 2006; 58(15):1688-713. https://doi.org/10.1016/j.addr.2006.09.017 PMid:17118485
69. Al-Qushawi A, Rassouli A, Atyabi F, Peighambari SM, Esfandyari-Manesh M, Shams GR, Yazdani A. Preparation and characterization of three tilmicosin-loaded lipid nanoparticles: physicochemical properties and in-vitro antibacterial activities. Iranian Journal of Pharmaceutical Research: IJPR. 2016; F15 (4):663.
70. Akhoond Zardini A, Mohebbi M, Farhoosh R, Bolurian S. Production and characterization of nanostructured lipid carriers and solid lipid nanoparticles containing lycopene for food fortification. Journal of food science and technology. 2018; 55(1):287-98. https://doi.org/10.1007/s13197-017-2937-5 PMid:29358821 PMCid:PMC5756214
71. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innovative Food Science & Emerging Technologies. 2013; 19:29-43. https://doi.org/10.1016/j.ifset.2013.03.002
72. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids and Surfaces B: Biointerfaces. 2005; 45(3-4):167-73. https://doi.org/10.1016/j.colsurfb.2005.08.005 PMid:16198092
73. Nastruzzi C. Lipospheres in drug targets and delivery: approaches, methods, and applications. CRC Press; 2004. https://doi.org/10.1201/9780203505281
74. Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, Duan CX, Zhang Q. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug delivery. 2010; 17(1):11-8. https://doi.org/10.3109/10717540903431586 PMid:19941406
75. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids and surfaces B: Biointerfaces. 2007; 60(2):174-9. https://doi.org/10.1016/j.colsurfb.2007.06.011 PMid:17656075
76. Keivani Nahr F, Ghanbarzadeh B, Samadi Kafil H, Hamishehkar H, Hoseini M. The colloidal and release properties of cardamom oil encapsulated nanostructured lipid carrier. Journal of Dispersion Science and Technology. 2020; 42(1):1-9. https://doi.org/10.1080/01932691.2019.1658597
77. Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. Journal of advanced research. 2016; 7(3):423-34. https://doi.org/10.1016/j.jare.2016.03.002 PMid:27222747 PMCid:PMC4856836
78. Yew HC, Misran M. Characterization of fatty acid based nanostructured lipid carrier (NLC) and their sustained release properties. Progress in Drug Discovery & Biomedical Science. 2019; 2(1). https://doi.org/10.36877/pddbs.a0000022
79. Gordillo-Galeano A, Ponce A, Mora-Huertas CE. In vitro release behavior of SLN, NLC, and NE: An explanation based on the particle structure and carried molecule location. Journal of Drug Delivery Science and Technology. 2022; 76:103768. https://doi.org/10.1016/j.jddst.2022.103768
80. Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Advanced pharmaceutical bulletin. 2022; 13(3):446. https://doi.org/10.34172/apb.2023.056 PMid:37646052 PMCid:PMC10460807
81. Kravicz M, Taiarol L, Viegas JS, Sierri G, Mauri M, Koch M, Steinkühler C, Re F. Nanostructured lipid carrier formulation for delivering poorly water-soluble ITF3756 HDAC inhibitor. Journal of Drug Delivery Science and Technology. 2024; 101:106238. https://doi.org/10.1016/j.jddst.2024.106238
82. Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs-barriers of translation and solutions. Aaps Pharmscitech. 2014; 15(4):822-33. https://doi.org/10.1208/s12249-014-0107-x PMid:24687241 PMCid:PMC4113620
83. Alavi SE, Bakht U, Koohi Moftakhari Esfahani M, Adelnia H, Abdollahi SH, Ebrahimi Shahmabadi H, Raza A. A PEGylated nanostructured lipid carrier for enhanced oral delivery of antibiotics. Pharmaceutics. 2022; 14(8):1668. https://doi.org/10.3390/pharmaceutics14081668 PMid:36015294 PMCid:PMC9415149
84. Tian C, Asghar S, Wu Y, Kambere Amerigos D, Chen Z, Zhang M, Yin L, Huang L, Ping Q, Xiao Y. N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Drug delivery. 2017; 24(1):1605-16. https://doi.org/10.1080/10717544.2017.1391890 PMid:29063815 PMCid:PMC8241171
85. Khan S, Shaharyar M, Fazil M, Hassan MQ, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. European Journal of Pharmaceutics and Biopharmaceutics. 2016; 109:149-57. https://doi.org/10.1016/j.ejpb.2016.10.011 PMid:27793753
86. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. European journal of pharmaceutics and biopharmaceutics. 2009; 71(2):161-72. https://doi.org/10.1016/j.ejpb.2008.09.003 PMid:18824097
87. Santonocito D, Puglia C. Applications of lipid-based nanocarriers for parenteral drug delivery. Current Medicinal Chemistry. 2022; 29(24):4152-69. https://doi.org/10.2174/0929867329666220104111949 PMid:34983336
88. Varrica C, Carvalheiro M, Faria-Silva C, Eleutério C, Sandri G, Simões S. Topical allopurinol-loaded nanostructured lipid carriers: a novel approach for wound healing management. Bioengineering. 2021; 8(12):192. https://doi.org/10.3390/bioengineering8120192 PMid:34940345 PMCid:PMC8698943
89. Aliasgharlou L, Ghanbarzadeh S, Azimi H, Zarrintan MH, Hamishehkar H. Nanostructured lipid carrier for topical application of N-acetyl glucosamine. Advanced pharmaceutical bulletin. 2016; 6(4):581. https://doi.org/10.15171/apb.2016.072 PMid:28101465 PMCid:PMC5241416
90. Ghate VM, Lewis SA, Prabhu P, Dubey A, Patel N. Nanostructured lipid carriers for the topical delivery of tretinoin. European Journal of Pharmaceutics and Biopharmaceutics. 2016; 108:253-61. https://doi.org/10.1016/j.ejpb.2016.07.026 PMid:27519827
91. Gaikwad S, Kasture A. Nanostructured lipid carriers in cosmeceuticals. Int J Creat Res Thoughts. 2024; 12(5):317-322.
92. Wissing SA, Müller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. European Journal of Pharmaceutics and Biopharmaceutics. 2003; 56(1):67-72. https://doi.org/10.1016/S0939-6411(03)00040-7 PMid:12837483
93. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opinion on Drug Delivery. 2012; 9(4):429-41 https://doi.org/10.1517/17425247.2012.666967 PMid:22394125
94. Mohanty D, Alsaidan OA, Zafar A, Dodle T, Gupta JK, Yasir M, Mohanty A, Khalid M. Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation. Pharmaceutics. 2023; 15(7):1985. https://doi.org/10.3390/pharmaceutics15071985 PMid:37514171 PMCid:PMC10386213
95. Cunha S, Forbes B, Sousa Lobo JM, Silva AC. Improving drug delivery for Alzheimer's disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. International journal of nanomedicine. 2021: 4373-90. https://doi.org/10.2147/IJN.S305851 PMid:34234432 PMCid:PMC8256381
96. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert opinion on drug delivery. 2013; 10(7):957-72. https://doi.org/10.1517/17425247.2013.790887 PMid:23586809
Published
Abstract Display: 201 
PDF Downloads: 151 PDF Downloads: 51 How to Cite
Issue
Section
Copyright (c) 2025 R Prema , M Prabhakaran , M Meenakshi, C Sankar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.